Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 13/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756632 | 0.82 | LMNA (0.50) | ALDH1A1MAPK1MEN1LMNAKMT2A | |
| SCHEMBL7957424 | 0.82 | ANO1 (0.57) | ANO1MEN1KMT2A | |
| SCHEMBL12756765 | 0.81 | ALDH1A1 (0.41) | ANO1ALDH1A1MAPK1MEN1LMNA | |
| SCHEMBL12756629 | 0.78 | NPSR1 (0.47) | ANO1ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL1490241 | 0.78 | ALOX15 (0.53) | MAPK1MEN1LMNAKMT2AMAPT | |
| SCHEMBL12756711 | 0.77 | RAB9A (0.55) | MEN1LMNAKMT2AMAPTHPGD | |
| SCHEMBL12756631 | 0.76 | NPY5R (0.51) | ALDH1A1MAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12756649 | 0.76 | HCAR2 (0.43) | ANO1MAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12756545 | 0.76 | ANO1 (0.49) | ANO1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL12756687 | 0.75 | NPSR1 (0.53) | ANO1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ALDH1A1 4409/4885MAPK1 2526/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ALDH1A1 4409/4885MAPK1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.